Image Source : FILE PHOTO 500-600 Covid centres in section 1 of vaccination: Delhi govt
The Delhi authorities on Sunday introduced it will run 500 to 600 Covid centres within the first section of vaccination quickly after the Drug Controller General of India (DCGI) provides approval to Serum Institute of India’s ‘Covishield’ vaccine and Bharat Biotech’s ‘Covaxin’ for emergency use.
Delhi Health Minister Satyendar Jain made the announcement throughout a press convention whereas commenting on the protocol that will probably be adopted for the rollout of the vaccine.
The minister mentioned “500-600 Covid centres will be set up in the first phase and it will be further escalated to 1,000. Storage facilities have been made. Ultimately, 1,000 centres will be there.”
On the approval of the vaccine by DCGI, Jain mentioned, “we have just been made aware that the vaccines developed by Bharat Biotech and Serum Institute of India have been given approval.”
“Delhi government is making all the arrangements. The protocol will be that health care and frontline workers, people over 50 years of age or with co-morbidities will be injected in the first phase of the roll-out,” mentioned Jain.
“Delhi has 3 lakh healthcare workers and 6 lakh frontline workers. The vaccine will be first rolled out to these 9 lakh people.”
The minister mentioned that Delhi authorities is totally prepared for the rollout.
He mentioned a dry run was performed on Saturday in three several types of centres — authorities hospitals, non-public hospitals and authorities dispensaries.
Commenting on the de-escalation of Covid beds in Delhi, the minister mentioned de-escalation was performed in Delhi just a few days again.
“Under this, we had decreased some 2,500 beds in Delhi authorities hospitals and 5,000 to six,000 beds in non-public hospitals. The occupancy at the moment is lower than 2,000. Earlier we had 18,800 beds out there, however even after de-escalation, we nonetheless have 10,500 to 11,000 beds. We shall be repeating the train of de-escalation subsequent week.
“We are very closely reviewing the situation, but we are treading very cautiously. We are over-cautious.”
ALSO READ | Bharat Biotech will get licensing permission to fabricate Covaxin
Latest India News
